Clinical Trial Update: Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update indicates Patritumab Deruxtecan (U3-1402) is being studied in unresectable locally advanced or metastatic breast cancer and is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Patritumab Deruxtecan (U3-1402) (patritumab deruxtecan)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Status: RECRUITING